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Abstract 
Introduction: In recent years, new psychoactive substances (NPS) have been widely 
distributed for abuse purposes. Effective measures to counter the spread of NPS are to 
promptly legislate them through the risk assessment. Phencyclidine analogues having 
inhibitory effects toward NMDA receptor (NMDAR) have recently emerged in Japan. 
Therefore, it is important to establish a high-throughput system for efficiently detecting 
NPS that can inhibit NMDAR activity. Methods: Hippocampal neurons prepared from 
embryonic rats were incubated in 96-well microplates. After 3 weeks in vitro, cultured 
neurons were preincubated with phencyclidine (PCP) or PCP-analogues, including 3-
methoxyphencyclidine (3-MeO-PCP) and 4-[1-(3-
methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo), and then treated with 100 µM 
glutamate for 10 min. After fixation, cultured neurons were immunostained with anti-
drebrin and anti-MAP2 antibodies. The linear cluster density of drebrin along the 
dendrites was automatically quantified using a protocol that was originally developed by 
us. Results: The high-throughput immunocytochemical assay, measuring drebrin cluster 
density of cultured neurons, demonstrated that glutamate-induced reduction of drebrin 
cluster density in 96-well plates is competitively inhibited by NMDAR antagonist, APV. 
The reduction was also antagonized by PCP, 3-MeO-PCP and 3-MeO-PCMo. The 
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inhibitory activity of 3-MeO-PCMo was lower than that of PCP or 3-MeO-PCP, with IC50 
values of 26.67 µM (3-MeO-PCMo), 2.02 µM (PCP) and 1.51 µM (3-MeO-PCP). 
Discussion: The relative efficacy among PCP, 3-MeO-PCP and 3-MeO-PCMo calculated 
from IC50 are similar to those from Ki values. This suggests that the high-throughput 
imaging analysis is useful to speculate the Ki values of new PCP analogues without 
performing the kinetic studies.  
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1. Introduction 
New psychoactive substances (NPS) are marketed using terms such as “legal highs” 
“bath salts” or “research chemicals”; however, they are substances of abuse with effects 
similar to that of drugs under international control (UNODC, 2017). The emergence of 
NPS has been reported by > 100 countries and territories worldwide and their distribution 
has increased the public health concern in many nations. Therefore, it is important to 
facilitate the accumulation of the relevant data and analysis available on NPS to promptly 
legislate these substances through a risk assessment process.  
NPS with NMDA receptor (NMDAR) inhibitory activity have recently emerged, 
including methoxethamine and diphenidine (Hondebrink et al., 2017; Kang et al., 2017; 
Kikura-Hanajiri, 2014; Kikura-Hanajiri, 2017; Roth et al., 2013). Although NMDAR is 
primarily involved in learning and memory in the central nervous system, if NMDAR 
activity is reduced, amnesia, perceptual alterations, hallucinations and delusions can occur. 
This effect involving perceptual and spiritual phenomena can lead to the use of NMDAR 
inhibitors as abused drugs, with these substances likely having dangerous effects similar 
to that of narcotics (Morris & Wallach, 2014). 
Regarding the detection of NMDAR inhibitory activity, there are two ways in which it 
can be measured. The first is the calcium imaging method (Ring & Tanso, 2007; Sato et 
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al., 2016), whereas the second is the displacement assay using tritium labeled MK801 
with isotopes (Reynolds, 2001). These assays are useful because of their respective 
characteristics; however, they cannot directly, simply, or quickly measure NMDAR 
inhibitory action because of their inability to directly measure the action on NMDAR, 
their complicated operation, or the use of a radioisotope. 
Cultured neurons gradually extend dendrites during incubation and represent 
matured synapses between neurons; in 3 weeks, the structure called “dendritic spine” 
having a mushroom-shaped head is completed. In the dendritic spine, drebrin is 
accumulated at high concentrations with actin filaments, and stabilizes the dynamics of 
receptors and scaffold proteins in dendritic spines (Sekino et al., 2007; Shirao et al., 2017). 
Glutamate treatment on neurons induces rapid drebrin exodus from dendritic spines 
(Sekino et al., 2006; Mizui et al., 2014). Although administered glutamate activates both 
AMPAR and NMDAR, the drebrin exodus is specifically induced with NMDAR 
activation, and is quantitative (Koganezawa et al., 2017; Mizui et al., 2014; Sekino et al., 
2017). 
We have recently developed a high-throughput imaging analysis of the linear density 
of drebrin clusters along dendrites for detecting synaptic status, which is sensitive enough 
to detect the effects of glutamate receptor activation on synapses (Hanamura et al. 
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submitted to the same special issue of J. Pharmacol. Toxicol. Methods).  In this study, 
we use this method in the evaluation of the inhibitory activity of two phencyclidine (PCP) 
analogues, with PCP used as the positive control. The inhibitory activity of 3-
methoxyphencyclidine (3-MeO-PCP) and 4-[1-(3-
methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) is determined by measuring the 
reduction in the linear density of drebrin clusters after glutamate stimulation to NMDAR.  
 
2. Methods 
2.1. Animals.Animal experiments were performed according to the guidelines set by the 
Animal Care and Experimentation Committee (Gunma University, Showa Campus, 
Maebashi, Japan) and conformed to NIH guidelines for the use of animals in research. 
All efforts were made to minimize animal suffering and to reduce the number of animals 
used. Pregnant Wistar rats were obtained from Charles River Japan Inc. (Yokohama, 
Japan). Animals were maintained under standard animal facility conditions with free 
access to food and water. 
 
2.2. Hippocampal neuronal culture. Frozen neurons prepared from the hippocampus of 
embryonic day 18 rats were seeded on 96-well plates pre-coated with poly-Lysine  
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(Thermo 96 Well Black Poly Bottom Poly-Lysine，152037, ThermoFisher Scientific, 
Waltham, MA, USA) at a density of 3.0×104 cells per cm2 using Neurobasal Medium 
containing B27 supplement, penicillin / streptomycin and L-alanyl-L-glutamine 
(Glutamax-I) (ThermoFisher Scientific) and incubated at 37°C, 5% CO2. At 4 days in 
vitro (DIV), Cytosine -D-arabino-furanoside (Sigma, St. Louis, MO, USA) was added 
to a final concentration of 0.2 μM to reduce the growth of glia. After the neurons were 
cultured for 21 DIV, they were pharmacologically treated. 
 
2.3. Administration of drugs. PCP, 3-MeO-PCMo, and 3-MeO-PCP (Cayman Chemical, 
Ann Arbor, MI, USA) were diluted to predetermined concentrations in a 0.1% DMSO 
solution and administered in cultured neural cells in the prescribed wells of the 96-well 
plates. Glutamate (Wako Pure Chemical Industries, Ltd., Osaka, Japan) solution was 
prepared such that the final concentration in the wells was 100 µM and was administered 
10 min after the administration of the drug solution. For the experiments to obtain dose 
response curve of drebrin cluster density, final glutamate concentration was 1, 3, 10, 30, 
50 or 100 µM. Some neurons were treated by APV (an NMDAR competitive antagonist, 
50, 100 or 500 µM) for 10 min before the glutamate treatments. 
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2.4. Immunocytochemistry. The cultured neurons were fixed with 4% paraformaldehyde 
in phosphate buffer. After permeabilization with 0.1% Triton X-100 in phosphate 
buffered saline (PBS) for 5 min, the neurons were blocked with 3% bovine serum albumin 
in PBS (PBSA) for 1 h at room temperature (RT), then incubated with primary antibodies 
overnight at 4°C. Anti-drebrin antibody (mouse monoclonal, M2F6, 1:1) and anti-MAP2 
antibody (rabbit polyclonal, 1:2000, Merck Millipore, Darmstadt, Germany) were used 
as primary antibodies. After washing with PBS, the cells were incubated with secondary 
antibodies and 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI, 1:1000, 
ThermoFisher Scientific) for 1 h at RT. Secondary antibodies used were Alexa Fluor 488 
donkey anti-mouse IgG (1:250, Jackson ImmunoResearch Laboratories, Inc. West Grove, 
PA, USA.) and goat Alexa Fluor 594 donkey anti-rabbit IgG (1:250, Jackson 
ImmunoResearch Laboratories, Inc.). 
 
2.5. Automatic acquisition of images and analysis. The triple-stained images of the 
hippocampal neural cells cultured in the 96-well plates were automatically acquired (20× 
lens, numerical aperture 0.45) by using the automatic focus function of an IN Cell 
Analyzer 2200 (GE Healthcare, Chicago, IL, USA)． All of the data were collected at 
2048 × 2048 resolution at 16 bits/pixel and a single pixel in the image corresponded to a 
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325 nm square in the specimen plane. The obtained images were analyzed by IN Cell 
Developer Toolbox (GE Healthcare) using a newly developed protocol (Hanamura et al. 
submitted to the same special issue of J. Pharmacol. Toxicol. Methods), and quantified 
the linear density of drebrin clusters along dendrite. 
 
2.6. Statistics. Data were statistically analyzed by t-test or Turkey-Kramer's test following 
ANOVA with p values 0.05 being considered significant (Statcel4 Excel statistics, The 
publisher OMS Ltd, Tokyo, Japan). All data are presented as mean ± standard error of the 
mean (S.E.M.). Commercial software (GraphPad Prism8, Graphpad software com, San 
Diego, CA, USA) was used to draw the dose fitting curve and calculate EC50 and IC50. 
 
3. Results 
3.1 Glutamate treatment decreased drebrin cluster density through NMDAR activation 
 First, we determined the effects of glutamate on drebrin cluster density using our high-
throughput imaging system. Rat hippocampal cultured neurons were treated by several 
concentration of glutamate (1 µM, N = 61; 3 µM, N = 97; 10 µM, N = 88; 30 µM, N = 
97; 50 µM, N = 20; 100 µM, N = 106) at 21 days in vitro (DIV). After 
immunocytochemistry, image acquisitions and analysis were done by automatically. 
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Obtained glutamate dose response curve of drebrin cluster density is shown in Figure 1A. 
EC50 was 10.4 μM with the 95% confidence interval (CI) ranging from 6.29 μM to 17.4 
μM. 
We also determined that this decrease of drebrin cluster density by glutamate 
stimulation is blocked by applying APV (50 µM, N = 4; 100 µM, N = 7; 500 µM, N = 6) 
to some extent (Figure 1B). The results indicate that our high-throughput imaging system 
is able to detect the reduction of drebrin cluster density by glutamate stimulation and its 
blockage by an NMDAR competitive antagonist. 
 
3.2 Inhibitory effect of PCP, 3-MeO-PCMo and 3-MeO-PCP on glutamate-induced 
decrease of drebrin cluster density. 
First, we determined to what extent the density of the drebrin clusters would be reduced 
using 100 μM glutamate (control; N = 95, glutamate 100 µM; N = 77). As shown in 
Figure 2A, 100 μM glutamate reduced the drebrin cluster density approximately 40% of 
the control group (control; 0.538 ± 0.0143, 100 µM glutamate; 0.319 ± 0.0035). 
We then investigated the inhibitory effect of PCP, a noncompetitive antagonist of 
NMDAR, on the reduction in the density of the drebrin clusters by NMDAR stimulation 
with glutamate (0–10 µM, N = 18). The average inhibition rate of each administration 
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group against the control group was calculated to analyze the dose-dependent effects. 
Figure 2B shows that PCP significantly inhibited the reduction of drebrin clusters at a 
concentration of ≥1 μM by NMDAR stimulation of the 100 µM glutamate, and PCP 
inhibited the reduction of the drebrin clusters in a dose-dependent manner. 
Moreover, we investigated the inhibitory action of PCP analogues, 3-MeO-PCP and 
3-MeO-PCMo, in the similar manner (0–10 µM, 3-MeO-PCP; N = 29, 3-MeO-PCMo; 
N = 30). Figure 2C shows that 3-MeO-PCP significantly inhibited the reduction of the 
drebrin clusters by 100 µM glutamate at a concentration of ≥333 nM. Figure 2D shows 
that 3-MeO-PCMo inhibited significantly that at a concentration of ≥3.33 µM. In 
addition, both 3-MeO-PCP and 3-MeO-PCMo inhibited the reduction of the drebrin 
clusters in a dose-dependent manner. 
 
3.3 IC50 values of PCP, PCP, 3-MeO-PCMo and 3-MeO-PCP 
To increase the quantitative reliability of the analysis, the dose-effect curve was 
created, which was curve-fitted based on a theoretical formula (Gesztelyi et al., 2012; 
Gadagkar & Call, 2015) to evaluate the difference by comparing the actions of PCP and 
3-MeO-PCP or 3-MeO-PCMo. In addition, the inhibitor concentration that reduces 
activity by half maximal inhibitory concentration (IC50) values of each substance were 
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measured. Figure 3 shows that the inhibitory activity of 3-MeO-PCP was comparable to 
that of PCP and the inhibitory activity of 3-MeO-PCMo was lower than that of PCP, with 
IC50 values of PCP = 2.02 µM (95%CI 1.39-2.97), 3-MeO-PCP =1.51 µM (95%CI 1.16 
-1.99), 3-MeO-PCMo = 26. 7 µM (95%CI 20.0-37.3).  
 
4. Discussion 
In this study, we quantified the IC50 values of PCP, 3-MeO-PCP and 3-MeO-PCMo by 
measuring drebrin cluster density using a high-throughput imaging analysis that we 
recently developed, and demonstrated that the order of inhibitory activity was 3-MeO-
PCP > PCP > 3-MeO-PCMo. In this part, we discuss the usefulness of measuring drebrin 
cluster density to calculate IC50 and speculate Ki values of PCP analogues using the high-
throughput analysis system. Furthermore, we discuss its use in safety pharmacology study 
from the view of pharmacodynamic of NMDAR antagonism. 
NMDAR is composed of four subunits, comprising two sets of heterodimers, namely 
NR1 and NR2. NMDAR has a PCP binding site. PCP, MK801 or ketamine binds to 
NMDAR, exerting their effect by inhibiting NMDAR activity (Dingledine et al., 1999; 
Paoletti & Neyton, 2007; Lee et al., 2014). 
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PCP acts as a dose-dependent NMDAR inhibitor by blocking the open channel pore, 
and has a high affinity for the PCP binding site of NMDAR (Wallach & Brandt, 2018; 
Wallach 2014; Lodge & Mercier, 2015). In recent studies involving binding assays 
toward NMDAR, inhibition constant (Ki) values of PCP and 3-MeO-PCP have been 
reported as 57.9 nM and 38.1 nM, respectively (Wallach, 2014). In contrast, the Ki value 
of PCP and 3-MeO-PCMo have been reported as 22.1 nM and 252.9 nM, respectively 
(Colestock et al., 2018). The affinity ratio against PCP from the above Ki values were 
calculated. The results were 3-MeO-PCP = 0.73 (recalculation from Ki value of “Wallach 
2014”), 3-MeO-PCMo = 11.4 (recalculation from Ki value of “Colestock et al., 2018”) 
as PCP = 1. In summary, the order of affinity appears to be comparable to that of their 
PCP counterparts, with 3-MeO-PCP > PCP > 3-MeO-PCMo. 
The relationship between Ki and IC50 varies. However, when a group of inhibitory 
compounds have an identical mechanism of action, a direct comparison of the IC50 values 
among them suffices to determine the relative efficacy (Cheng & Prusoff, 1973; Cer et 
al., 2009). PCP and other high-affinity NMDAR antagonists have been suggested to have 
a similar inhibitory mechanism of NMDAR (Lodge & Mercier, 2015). Therefore, the 
potency ratio against PCP from the IC50 values obtained in this study were calculated, the 
results were 3-MeO-PCP = 0.75, 3-MeO-PCMo = 13.2 as PCP = 1. Thus, the relative 
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efficacy among PCP, 3-MeO-PCP and 3-MeO-PCMo calculated from IC50 are similar to 
those from Ki values. Consequently, the IC50 value obtained from this system reflects 
NMDAR antagonist action and can be used for the pharmacological evaluation (toxicity 
evaluation) of NPS with NMDAR inhibitory activity.  
When the Ki values of NPSs are required, it may be impractical to perform the kinetic 
studies required to determine the Ki for each (Cheng & Prusoff, 1973). However, if the 
Ki of one compound that have a similar inhibitory mechanism, the Ki values can be 
calculated from IC50. Considering that this high-throughput analysis can efficiently 
provide related data at varying drug concentrations with one measurement, this system is 
useful as an evaluation system for detecting the inhibitory action on the glutamate 
NMDAR for the risk assessment of NPS. 
Some studies have reported that the in vitro potencies of NMDAR antagonists closely 
correlate with the affinities reported by PCP binding assays, with the PCP analogues 
discrimination in animal models correlating well with the affinities toward the PCP site 
of NMDAR (Lodge & Mercier, 2015). However, the correlating potency of NMDAR 
antagonists with dysphoric and psychotomimetic potency in humans was more tenuous 
(Lodge & Mercier, 2015). If neurons derived from human iPS cells are subjected to the 
Mitsuoka et al., Journal of Pharmacological and Toxicological Methods 
16 
 
high-throughput drebrin immunocytochemical assay in future studies, accurate 
interpolation of toxicity of these substances to humans may be possible. 
In addition, this evaluation system for detecting the inhibitory action on the glutamate 
NMDAR may be applied to drug development related to neuroprotective effects. The 
excitotoxicity of NMDAR is a target for drug development toward a wide variety of 
neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), 
neuropathic pain, glaucoma and vascular dementia (Couratier et al., 1996; Lipton, 2006; 
Rogawski & Wenk, 2003; Zurakowski et al., 1998). In the subsequent safety 
pharmacology, it is important to predict mechanism-based pharmacological action, 
because animal tests have limitations on detecting symptoms like amnesia and 
hallucination caused by NMDAR antagonism. Thus, our evaluation system can be used 
for drug discovery and safety pharmacology. 
Especially, the pharmacodynamic data play an important role when the consideration 
of initial dose in a first-in-human clinical trial (European Medicines Agency, 2017). The 
prediction of pharmacological actions based on the characteristics of NMDAR, such as 
cellular response consequent to the interaction with NMDAR, duration and reversibility 
of effect, and dose-response relationships, would be useful for predicting species 
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differences in pharmacology, effects of genetic polymorphisms, and drug interactions. 
In vitro systems can be used in supportive studies to obtain a profile of the activity of 
the substance under the ICH S7A guidelines (ICH, 2000). The present 
immunocytochemical assay system is a robust analysis for NMDAR activity with high 
reproducibility, and does not require any special skills compared with 
electrophysiological method for detecting NMDAR activity. However, in terms of the 
limitation of our system in broad applicability to drug safety study use, our system can 
detect inhibitory activity of NMDAR but not other types of receptors. After a greater 
evaluation of central nervous system (CNS) and non-CNS drugs is performed using our 
system, ambiguities on the scope of applicable substances and the magnitude of false 
negative and/or false positive will be clarified. 
Taken together, this system might be used as a part of CNS safety pharmacology in the 
future. 
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Figure legends  
 
Figure 1. Glutamate dose response curve of drebrin cluster density. (A) Drebrin cluster 
density were normalized by the average density of control group (N = 61). The dose 
response curve were fitted based on the theoretical formula: Y = Bottom + (1−Bottom) 
/ (1+10^ ((LogEC50−X) * HillSlope)). Cultured neurons at DIV 21 were treated with 
several dose of glutamate (1, 3, 10, 30, 50 or 100 µM) for 10 min. Each dot indicates 
individual values (1 µM, N = 61; 3 µM, N = 97; 10 µM, N = 88; 30 µM, N = 97; 50 µM, 
N = 20; 100 µM, N = 106). (B) To examine the effect of an NMDAR antagonist, some 
neurons were treated with APV (50 µM, N = 4; 100 µM, N = 7; 500 µM, N = 6) 10 min 
prior to the glutamate treatments. The dose response curve for APV (0 µM) is the same 
as that of Figure 1A. Data are presented as mean ± S.E.M. 
 
Figure 2. Effects of drug treatments on the drebrin cluster density. (A) Effects of 
glutamate treatment. Upper panel shows representative images of neurons (MAP2 (red), 
drebrin clusters (green or monochrome) compared 100 µM glutamate administration to 
naive control．Lower panel shows quantitative analysis of drebrin cluster density (/µm 
dendrite). Data are presented as mean ± S.E.M. * p < 0.05, t-test. (B) Inhibitory potency 
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of PCP on the reduction of drebrin clusters by glutamate. Administration group (0.1 nM-
10 µM) was normalized by assuming that the average value of the control group was 
100%, and that the average value of the 100 µM glutamate administration group was 0%. 
Administration groups at 1 μM or more significantly inhibited the reduction of drebrin 
clusters. Values are expressed as mean ± S.E.M., * p < 0.05 vs control by Turkey-
Kramer's test. (C) Inhibitory potency of 3-MeO-PCP on the reduction of drebrin clusters 
by glutamate. Administration group (0.1 nM-10 µM) was normalized by assuming that 
the average value of the control group was 100%, and that the average value of the 100 
µM glutamate administration group was 0%. Administration groups of 3-MeO-PCP at 
333 nM or more significantly inhibited the reduction of drebrin clusters. Values are 
expressed as mean ± S.E.M., * p < 0.05 vs control by Turkey-Kramer's test. (D) Inhibitory 
potency of 3-MeO-PCMo on the reduction of drebrin clusters by glutamate. 
Administration group (0.1 nM-10 µM) was normalized by assuming that the average 
value of the control group was 100%, and that the average value of the 100 µM glutamate 
administration group was 0%. Administration groups of 3-MeO-PCMo at 3.33 µM or 
more significantly inhibited the reduction of drebrin clusters. Values are expressed as 
mean ± S.E.M., * p < 0.05 vs control by Turkey-Kramer's test. Scale bars, 20 µm in A, 
10 µm in B, C and D. 
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Figure 3. Comparison of inhibitory potencies of PCP, 3-MeO- PCP and 3-MeO-PCMo 
on the reduction of drebrin clusters by glutamate. Each administration group (0.1 nM-10 
µM) was normalized by assuming that the average value of the control group was 0%, 
and that the variation from average value of 100 µM glutamate administration group to 
the average value of the control group was 100%. Dose response curve was fitted based 
on the theoretical formula. In addition, IC50 were calculated by fitting curves. IC50 of PCP, 
3-MeO-PCP and 3-MeO-PCMo were 2.02 µM, 1.51 µM and 26.7 µM, respectively. 
Values are expressed as mean ± S.E.M. 
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